Fwd: Pfizer and Arvinas Announce a New Education RFP in Metastatic Breast Cancer.

[Okechukwu Ogah]

Dr O.S Ogah. MBBS, MSc, PhD, MD, FWACP, FACP, FESC, FNCS

A. Senior Lecturer

Cardiology Unit, Department of Medicine,

Faculty of Clinical Sciences

College of Medicine,

University of Ibadan, NIGERIA

B. Honorary Consultant Physician/Cardiologist,

Cardiology Unit,

Department of Medicine

University College Hospital Ibadan, NIGERIA

PERSONAL POSTAL ADDRESS

P.O BOX 14343, UNIVERSITY OF IBADAN  POST OFFICE

IBADAN, NIGERIA

Tel. +234 806 77 47 121
Fax. +1215-975-6817 (Electronic)
Emails: 

oso...@com.ui.edu.ng ,

osoga...@gmail.com

osoga...@yahoo.com

https://www.researchgate.net/profile/Okechukwu_Ogah4/contributions

C. Bernard Lown Visiting Scholar in Cardiovascular Health

Department of Global Health and Population

Harvard T.H. Chan School of Public Health

Email: oo...@hsph.harvard.edu

D. Adjunct Researcher,

Institute of Advanced Medical Research and Training (IAMRAT)

College of Medicine, University of Ibadan, NIGERIA

E. Affiliate Member,

The Hatter Institute for Cardiovascular Research in Africa (HICRA)

4th Floor Chris Barnard Building
Faculty of Health Sciences
University of Cape Town
Private Bag X3 7935
Observatory, SOUTH AFRICA

http://www.hatter.uct.ac.za/icra/about/staff/visiting-researchers

F. Past President,

Nigerian Cardiac Society

--------------------------------------------------------------------------------------------------------------------------------------------------

"For with thee is the fountain of life: in thy light shall we see light." Psalm 36:9

-------------------------------------------------------------------------------------------------

---------- Forwarded message ---------
From: CRIM UNIT COMUI <crimo...@gmail.com>
Date: Fri, May 3, 2024 at 12:43 PM
Subject: Pfizer and Arvinas Announce a New Education RFP in Metastatic Breast Cancer.
To:

  Dear Ma/Sir,

I hope this email finds you well, Pfizer Inc. and Arvinas are collaborating to provide grant support for continuing professional education in Metastatic Breast Cancer. This competitive grant program seeks to support independent medical education activities focused on the evolving treatment landscape for patients with ER+/HER2- mBC. 

Applicants are encouraged to identify and address the educational needs of healthcare professionals related to novel treatments in the evolving clinical landscape of ER+/HER2- mBC.

For more information: click here

Request for Proposals (RFP) New Mechanisms and Emerging Treatment Options in Metastatic Breast Cancer

Pfizer Inc. and Arvinas are collaborating to provide grant support for continuing professional education in Metastatic Breast Cancer (mBC). This publicly posted Request for Proposals (RFP) provides details regarding a general area of interest, sets timelines for review and approval, and describes an internal company alliance review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the RFP. For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Neither Pfizer nor Arvinas may be involved in any aspect of project development, nor the conduct of the independent education program. Date RFP Issued: May 2, 2024 Geographic Scope: Global Clinical Area: Metastatic Breast Cancer (mBC) Link to full RFP: New Mechanisms and Emerging Treatment Options in Metastatic Breast Cancer Application Due Date: June 27, 2024 Specific Area of Interest: This competitive grant program seeks to support independent medical education activities focused on the evolving treatment landscape for patients with ER+/HER2- mBC. Projects that will be considered for grant support will focus on one or more of the following: Increasing understanding of emerging and novel therapeutic agents in the evolving treatment landscape of ER+/HER2- mBC Exploring the current unmet needs in ER+/HER2- mBC, including the relevance and applicability of biomarker testing Increasing understanding of differentiated MOA of emerging therapies including proteolysis targeting chimera estrogen receptor (PROTAC ER) degraders from that of other endocrine therapies (e.g., SERDs)

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to e Pfizer Grant Officer, Jacqueline Waldrop (Jacquelin...@pfizer.com) and the Arvinas Grants Director, Jennifer Schreiber (Jennifer....@arvinas.com).

You are receiving this e-mail because you are registered in the Pfizer Grant Management System (GMS) and/or have subscribed to receive communications from Pfizer Global Medical Grants. To continue receiving updates, please add globalmed...@pfizer.com to your address book.